Edition:
United Kingdom

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.44USD
18 Jan 2018
Change (% chg)

$0.08 (+0.96%)
Prev Close
$8.36
Open
$8.31
Day's High
$8.55
Day's Low
$8.16
Volume
123,423
Avg. Vol
491,139
52-wk High
$25.11
52-wk Low
$5.91

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $387.58
Shares Outstanding(Mil.): 36.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

08 Jan 2018

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

11 Dec 2017

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

02 Nov 2017

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

30 Oct 2017

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

03 Oct 2017

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

25 Sep 2017

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

25 Sep 2017

BRIEF-NewLink Genetics Q2 loss per share $0.57

* NewLink Genetics - ‍expect to end 2017 with approximately $75 million in cash and equivalents, which excludes any cash that may be received from financing​

28 Jul 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,392 +2.50
Pfizer Inc. (PFE.N) $36.99 -0.19
Novartis AG (NOVN.S) CHF82.90 -0.34
Merck & Co., Inc. (MRK.N) $61.13 -0.90
Roche Holding Ltd. (ROG.S) CHF233.20 -0.15
Roche Holding Ltd. (RO.S) CHF236.80 +1.00
Abbott Laboratories (ABT.N) $59.07 +0.08
Sanofi SA (SASY.PA) €72.37 -0.50
AstraZeneca plc (AZN.L) 4,980.50 -10.00
GlaxoSmithKline plc (GSK.L) 1,353.20 -6.00

Earnings vs. Estimates